NICE recommends RoActemra for early use in arthritis InPharm This updates its previous guidance (TA198) from last August, which said RoActemra should only be used for patients with RA if there has been an inadequate response to one or more TNF inhibitors, and when Roche's other RA drug MabThera (rituximab) had ... |
